Last updated: April 16, 2026
What is VAXCHORA and What is its market position?
VAXCHORA is a live, Oral Cholera Vaccine developed by PaxVax (acquired by Emergent BioSolutions in 2018). It is a single-dose oral vaccine targeting cholera, approved by the U.S. Food and Drug Administration (FDA) in December 2016. VAXCHORA is indicated for active immunization against cholera in adults 18 years and older. It is designed for travelers and populations at risk in cholera-endemic areas. Its key competitors include Dukoral by Valneva and Shanchol by Shantha Biotechnics.
What is the current market size for cholera vaccines?
The global cholera vaccine market was valued at approximately $180 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 7-10% through 2028. Growth drivers include increased global travel, urbanization, rising awareness of cholera risks, and strategic stockpiling by international health organizations.
Key market segments include:
- Travelers and military personnel: 35%
- Endemic regions: 40%
- Emergency response and outbreak control: 25%
How does VAXCHORA perform relative to competitors?
| Feature |
VAXCHORA (Euvichol-Plus) |
Dukoral |
Shanchol |
| Dosing |
Single dose |
Two doses, 1-6 weeks apart |
Two doses, 14 days apart |
| Storage |
2-8°C |
2-8°C |
2-8°C |
| Approval |
FDA, WHO, other regulators |
WHO, EMA |
WHO, India, others |
| Age range |
18+ |
2+ |
1+ |
| Indications |
Active travelers, endemic |
Travelers, endemic |
Endemic, outbreak |
VAXCHORA boasts ease of administration due to a single-dose schedule, which enhances compliance and suitability for outbreak response. However, the two-dose vaccines have longer-standing market presence and broader age indications, challenging VAXCHORA's market share.
What are the key factors influencing VAXCHORA's market trajectory?
Regulatory approvals
VAXCHORA's FDA approval in 2016 has permitted entry into the core U.S. travel market, with additional approvals in countries such as Canada, Norway, and Australia. WHO prequalification in 2018 expanded its use in global procurement programs.
Production capacity
PaxVax, now part of Emergent BioSolutions, scaled up manufacturing capacity since 2018, aiming to meet increasing demand. The company can produce approximately 20 million doses annually, with intentions to increase this capacity.
Public health demand
The World Health Organization (WHO) maintains cholera as a priority in emergency settings, with stockpiling programs such as the Global Cholera Vaccine Stockpile, which allocated nearly 20 million doses in 2022. VAXCHORA's single-dose regimen positions it favorably for such emergency deployments.
Competitive landscape
Dukoral remains the most widely used oral cholera vaccine globally, approved for children over 2 years and adults, with a two-dose schedule. Shanchol is low-cost and widely adopted in endemic countries. VAXCHORA competes primarily in the travel medicine segment and emergency response market.
Challenges
- Limited age indications: Only approved for adults 18+.
- Price point: VAXCHORA is priced higher than Shanchol, affecting procurement in low-resource settings.
- Market penetration: Greater awareness is needed among healthcare providers and travelers.
What is the projected financial outlook?
Emergent BioSolutions reported revenues from VAXCHORA of approximately $35 million in 2021, primarily from U.S. sales and international tenders. The company forecasts a compound annual growth rate of 12% through 2025, driven by increased adoption in emergency stockpiling and travel medicine.
Potential revenue segments:
- Travel Health Market: targeted growth as global travel recovers post-pandemic.
- Emergency Relief Funding: expanded procurement for outbreak response.
- Endemic Countries: limited penetration due to price and age restrictions.
Pricing strategies and production scale-up are expected to influence sales performance. Pricing is projected between $50-$70 per dose in high-income markets, with lower prices negotiated in endemic countries through GAVI and other agencies.
How might future developments influence VAXCHORA’s market?
Expanded approvals
Extension of age indications below 18 years could broaden market access, especially in endemic regions.
Combination vaccine development
Efforts to develop combined vaccines against cholera and other diarrheal diseases could impact VAXCHORA's market share.
Investment in manufacturing
Scaling production capacity beyond 20 million doses annually could meet growing global demand.
Market expansion
Increased procurement by the WHO and national governments, driven by improved emergency preparedness and travel industry recovery, will influence revenue growth.
What are the risks and opportunities ahead?
Risks:
- Competition from established vaccines like Dukoral.
- Regulatory delays in new indications.
- Pricing pressures in low-resource markets.
- Limited pediatric approval.
Opportunities:
- Broadening age indications.
- Increasing global health funding for cholera control.
- Growing awareness among travelers.
- Adoption for outbreak response in low-resource settings.
Key Takeaways
- VAXCHORA holds a niche in the travel medicine and emergency response markets with a single-dose schedule.
- The market is expanding, driven by international health initiatives and increased travel.
- Competition capitalizes on broader age ranges and established cost advantages.
- Future growth relies on regulatory expansions, manufacturing scale-up, and strategic market positioning.
FAQs
-
Will VAXCHORA seek approval for pediatric use?
PaxVax has not announced specific plans but may pursue pediatric approval to expand market access.
-
How does VAXCHORA pricing compare globally?
It is priced higher than Shanchol, with costs around $50-$70 per dose in high-income markets, and lower prices negotiated for endemic regions.
-
What is the supply outlook for emergency use?
Emergent BioSolutions can produce approximately 20 million doses annually, with the potential to increase manufacturing to meet rising demand.
-
What are regulatory barriers for market expansion?
Delays in obtaining approvals for younger age groups or additional indications could hinder growth.
-
How critical is VAXCHORA for global cholera control?
It complements existing vaccines in the emergency stockpile, offering logistical advantages, but its market share remains influenced by cost and age restrictions.
References
[1] MarketWatch. (2022). Cholera vaccine market size and forecast.
[2] Emergent BioSolutions. (2022). Annual report.
[3] WHO. (2022). Cholera vaccines: Global and regional access.
[4] PaxVax/Emergent. (2016). FDA approval of VAXCHORA.
[5] Valneva. (2022). Dukoral product profile.
